NewAmsterdam Pharma Company N.V. (NAMS)
NewAmsterdam Pharma Company N.V. (NAMS) is a healthcare company (biotechnology) based in the Netherlands. The share price is $19.30, down 0.82% on the day, which values the company at $2.31B. Price as of 17 Nov 2026, 17:29 UTC, from Yahoo Finance.
Key facts
- Share price
- $19.30−0.82% today
- Market value
- $2.31B
- Funk Score
- 27/100
- Against its own history
- Well above its usual priceusual price $14.83
- 200-week average
- $21.4410% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
NewAmsterdam Pharma Company N.V. in more detail
NAMS trades at -9.3× next year's expected earnings, 89.2× sales. Measured against its own history, the price is 30% above what its usual multiples would imply ($14.83) — well above its usual price. It sits 10% below its 200-week average of $21.44.
Its Funk Score is 27 out of 100 (financial strength 7.9, profitability 0.0, growth 1.7, value 1.1, each out of 10).
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.
5 of the superinvestors tracked here hold NAMS, including Peter Kolchinsky (2.8% of the portfolio), Stanley Druckenmiller (2.4% of the portfolio), Lee Ainslie (1.0% of the portfolio).
Superinvestors holding NAMS
5 of the investors tracked here report a position in their latest 13F filing.
- Peter Kolchinsky RA Capital Management2.81% of portfolio · $323.7M · Q2 2026
- Stanley Druckenmiller Duquesne Family Office2.39% of portfolio · $104M · Q2 2026
- Lee Ainslie Maverick Capital1.00% of portfolio · $110.7M · added · Q2 2026
- Andreas Halvorsen Viking Global Investors0.41% of portfolio · $142.5M · Q2 2026
- David Greenspan Slate Path Capital0.12% of portfolio · $7.8M · Q3 2026
NewAmsterdam Pharma Company N.V. (NAMS): questions and answers
What is NewAmsterdam Pharma Company N.V.'s market cap?
NewAmsterdam Pharma Company N.V. is valued at $2.31B at a share price of $19.30.
Is NAMS overvalued or undervalued?
Against its own history, NAMS is well above its usual price: the price is 30% above the $14.83 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is NAMS above its 200-week moving average?
No. NAMS is 10.0% below its 200-week average of $21.44. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is NewAmsterdam Pharma Company N.V. growing?
Over the last three fiscal years NewAmsterdam Pharma Company N.V.'s revenue grew -39.7% a year.
Does NAMS pay a dividend?
NewAmsterdam Pharma Company N.V. does not currently pay a regular dividend.
Which famous investors own NAMS?
In their latest quarterly filings, Peter Kolchinsky (2.8% of the portfolio), Stanley Druckenmiller (2.4% of the portfolio), Lee Ainslie (1.0% of the portfolio), Andreas Halvorsen (0.4% of the portfolio), David Greenspan (0.1% of the portfolio) hold NAMS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “NewAmsterdam Pharma Company N.V. (NAMS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/NAMS
Underlying data: Yahoo Finance; company filings with the SEC.